Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
Launched by NORTHWESTERN UNIVERSITY · Mar 19, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain factors can help predict whether patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will regain their sense of smell after being treated with a medication called dupilumab. The researchers want to find out if the blockage in a specific area of the nose, known as the olfactory cleft, and certain signals measured during breathing can indicate if a person will be able to smell again.
To participate in the study, candidates should be between the ages of 18 and 75, have a well-documented history of CRSwNP, and report experiencing a significant loss of smell for at least three months. Participants will have their olfactory cleft examined and monitored for six months while receiving treatment with dupilumab. This study is not yet recruiting, but if you're eligible, it could provide valuable insights into how this treatment affects the sense of smell.
Gender
ALL
Eligibility criteria
- • Well documented history of CRSwNP
- • BSIT age/sex classified as "abnormal" score
- • Self-reported stable olfactory deficit of moderate to severe quality \> 3 months
- • Prior endoscopic sinus surgery \>3 months, \<10 years prior
About Northwestern University
Northwestern University is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a robust infrastructure that supports interdisciplinary collaboration, Northwestern leverages its expertise in various fields, including medicine, engineering, and social sciences, to drive groundbreaking studies. The university is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring that all clinical trials are conducted with the utmost integrity and focus on participant safety. Through its Clinical Trials Office, Northwestern aims to translate scientific discoveries into effective therapies, ultimately enhancing health outcomes and contributing to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported